News
Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...
As explained in their conference abstract, HG302 is a one-time single-cut CRISPR-Cas12 therapy that is designed to induce exon skipping and restore dystrophin expression with minimal off-target ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will ...
6d
Stocktwits on MSNSarepta Shares Slide To 2017 Lows On Revenue Cut, But Retail Bulls Remain DefiantShares of Sarepta Therapeutics plunged more than 26% on Tuesday, falling to their lowest level since 2017, after the company ...
The U.S. Food and Drug Administration gave Capricor Therapeutics' application on deramiocel priority review, with a decision ...
A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...
A new study led by researchers at the Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...
Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will present preclinical data supporting the potential of ...
It is designed to enable targeted muscle tissue delivery and promote exon skipping in the nucleus, allowing muscle cells to create internally shortened, near full-length dystrophin protein, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results